AnaptysBio, Inc. ANAB Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Regeneron PharmaceuticalsREGN

$266.8M+13.8%

Dianthus TherapeuticsDNTH

$1.36M-2.3%

AbCellera Biologics Inc.ABCL

$143.22M+119%

Aclaris TherapeuticsACRS

$1.85M-21.8%

Avalo TherapeuticsAVTX

$242K-64.4%

Upstream Bio, Inc.UPB

$1.27M-30.8%

FAQ

What is AnaptysBio, Inc.'s operating lease liabilities (total)?

AnaptysBio, Inc. (ANAB) reported operating lease liabilities (total) of $13.61K in Q1 2026.

How has AnaptysBio, Inc.'s operating lease liabilities (total) changed year-over-year?

AnaptysBio, Inc.'s operating lease liabilities (total) decreased by 99.9% year-over-year, from $15.58M to $13.61K.

What is the long-term trend for AnaptysBio, Inc.'s operating lease liabilities (total)?

Over 5 years (2020 to 2025), AnaptysBio, Inc.'s operating lease liabilities (total) has grown at a -47.1% compound annual growth rate (CAGR), from $342K to $14.11K.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.